Urinary Prostanoid Metabolites and Serum Thromboxane Following Recovery from Cyclooxygenase Inhibition with Aspirin

Abstract

A previous study that measured urinary nary 11-dehydro-TXB₂, 114.4 ± 13.8%, and urinary thromboxane B₂ (TXB₂) and 6-keto-PGF_1α after with- TXB₂, 106.0 ± 12% (all not significant compared with drawal of aspirin found evidence of a rebound in urinary control). The urinary 6-keto-PGF_1α level 14 days after prostanoid excretion above control levels 14 days after aspirin withdrawal was 96.9 ± 17.8% of control (NS). aspirin administration ceased. This study aimed to con- Twenty-one days after aspirin withdrawal, TXB₂ metab firm these findings using a wider range of prostanoid me- olites as a percentage of control were, respectively, se tabolites. The subjects were 17 young, healthy volunteers rum TXB₂, 154 ± 39%; urinary TXB₂, 114 ± 11% (both who had taken 100 mg of enteric-coated aspirin daily for NS compared with control; and urinary 11-dehydro- 7 days followed by 650 mg of enteric-coated aspirin for a TXB₂, 127.2 ± 11.9% (p = 0.037 compared with control). further 7 days as part of another study. They showed Urinary 6-keto-PGF_1α 21 days after aspirin withdrawal signs of the expected inhibition of TXB₂ metabolites at was 159.9 ± 46.2% of control (NS). Overall there would the end of aspirin treatment. After 650 mg aspirin, serum appear to be a trend to increased production of prostanoid generation of TXB₂ by clotting blood was 0.77 ± 0.2% of metabolites 14 and 21 days after aspirin withdrawal, but it control (p < 0.0001), urinary 11-dehydro-TXB₂ was 21.8 reached statistical significance only for 11-dehydro-TXB₂ ± 2.8% of control (p < 0.0001), and urinary TXB₂ was at 21 days' withdrawal. As platelets are the major source 33.7 ± 4.2% of control (p < 0.0001). Fourteen days after of this metabolite, this finding would suggest that in- aspirin withdrawal, TXB₂ metabolites as a percentage of creased platelet generation of TXB₂ plays a part.

Keywords

Key control were respectively serum TXB2 163 ± 45%uri- Words: Aspirin—Platelets—Thromboxane A2.

Get full access to this article

View all access options for this article.

References

Vial JH , McLeod LJ , Roberts MS Rebound elevation in urinary thromboxane B2 and 6 keto PGF 1α excretion after aspirin withdrawal. In: Samuellson B , Ramwell PW , Paoletti R , et al., (eds). Advances in prostaglandins, thromboxane and leukotrienes research, vol. 21. 1991:157-60.

Vial JH , Narkowicz CK Comparison of cyclooxygenase inhibition with two different doses of enteric coated aspirin in normal young and elderly subjects and elderly with cerebrovascular disease. Clin Appl Thromb/Haemost 1994 ;1:00-00.

Patrono C. , Ciabattoni G. , Pinca E. , et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980;17:317-27.

Roberts MS , McLeod LJ , Cossum PA , Vial JH Inhibition of platelet function by a slow release acetylsalicylic acid formulation single and chronic dosing studies. Eur J Clin Pharmacol 1984;27:67-74.

Fitzgerald GA , Oates JA , Hawinger J. , et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983;71:676-688.

Catella F. , FitzGerald GA Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res 1987 ;47:647-56.

Vial JH , McLeod LJ , Roberts MS , et al. Selective inhibition of platelet cyclooxygenase with controlled release, low dose aspirin. Aust NZ J Med 1990 ;20:652-6.

Kudrow L. , Paradoxical effects of frequent analgesic use. Adv Neurol 1982;33:335-41.

Seibert K. , Masferrer JL , Jiyu F. , et al. The biochemical and pharmacological manipulation of cellular cyclooxygenase activity. In: Samuelsson B , Ramwell PW , Paoletti R , et al., eds. Advances in prostaglandin, thromboxane and leukotriene research, vol. 21. 1991:45-51.

10.

Vane J. Towards a better aspirin. Nature 1994;367:215-6.

11.

Bahl AK , Foreman JC , Dale MM The effect of prostaglandin E2 and non-steroidal anti-inflammatory drugs on cell-associated interleukin 1. In: Samuelsson B , Ramwell PW , Paoletti R , et al., eds., Advances in prostaglandin, thromboxane and leukotriene research. 1991:513-5.